By addressing both hyperglycemia and excess body weight, GLP-1 RA have become a cornerstone in the treatment of patients with T2DM, particularly those with concurrent obesity [2,5]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.